Resistance to clopidogrel: do we know everything?

Mesitskaia D.F.; Nikitina Yu.M.; Kopylov F.Iu.; Nesterova S.G.

doi:https://doi.org/

Mesitskaia D.F.

GBOU VPO "Pervyĭ MGMU im. I.M. Sechenova" Roszdrava, Moskva

Nikitina Yu.M.

GBOU VPO "Pervyĭ MGMU im. I.M. Sechenova" Roszdrava, Moskva

Kopylov F.Iu.

Pervyĭ MGMU im. I.M. Sechenova, kafedra profilakticheskoĭ i neotlozhnoĭ kardiologii FPPOV, Moskva

Scopus AuthorID: 6507736224
ORCID: 0000-0001-5124-6383

Nesterova S.G.

GBOU VPO "Pervyĭ MGMU im. I.M. Sechenova" Roszdrava, Moskva

Resistance to clopidogrel: do we know everything?

Authors:

Mesitskaia D.F., Nikitina Yu.M., Kopylov F.Iu., Nesterova S.G.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2013;6(1): 27‑32

Read: 3384 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Mesitskaia DF, Nikitina YuM, Kopylov FIu, Nesterova SG. Resistance to clopidogrel: do we know everything? Russian Journal of Cardiology and Cardiovascular Surgery. 2013;6(1):27‑32. (In Russ.)

Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Glucocorticoid-resistant forms of endocrine ophthalmopathy. Russian Annals of Ophthalmology. 2024;(6):125-130

Clinical and psychopathological features of treatment-resistant schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50

Rehabilitation of patients with post-COVID syndrome depending on C(159)T polymorphism of SD-14 gene. Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(1):42-50

Genome instability of the cholera agent: role in the evolution of pathogenicity, drug resistance and adaptation to a changing environment. Molecular Genetics, Microbiology and Virology. 2025;(2):3-13

Search for informative predictors of the development and progression of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):124-130

Abstract:

Keywords:

clopidogrel

resistance

genetic polymorphism

Authors:

Mesitskaia D.F.

GBOU VPO "Pervyĭ MGMU im. I.M. Sechenova" Roszdrava, Moskva

Nikitina Yu.M.

GBOU VPO "Pervyĭ MGMU im. I.M. Sechenova" Roszdrava, Moskva

Kopylov F.Iu.

Pervyĭ MGMU im. I.M. Sechenova, kafedra profilakticheskoĭ i neotlozhnoĭ kardiologii FPPOV, Moskva

Scopus AuthorID: 6507736224
ORCID: 0000-0001-5124-6383

Nesterova S.G.

GBOU VPO "Pervyĭ MGMU im. I.M. Sechenova" Roszdrava, Moskva

Close metadata

References:

Hankey G.L., Eikelboom J. Aspirin resistance. Lancet 2006; 367: 606-617.
Kuliczkowski W., Witkowski A., Polonski L. et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of Working Group on antiplatelet drugs resistanse appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009; 30: 426-435.
Snoep J.D., Hovens M.M., Eikenboom J.C. et al. Association of laboratory-defined aspirin resistance with a high risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-1599.
Michelson A. Platelet function testing in cardiovascular diseases. Circulation 2005; 10: 132-137.
Gurbel P.A., Blinder X.P., Bonnie L.H., O'Connor C.M. Clopidogrel for coronary stenting. Response variability, drug Resistance and effect of pretreatment platelet reactivity. Circulation 2003; 107: 23: 2908-2013.
Muller I., Besta F., Schulz C. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2004; 89: 783-787.
Matetzky S., Shenkman B., Guetta V. et al. Clopidogrel resistance is associated with increased risk if recurrent events in patients with acute myocardial infarction. Circulation 2004; 109: 1-5.
Angiolillo D.J., Fernández-Ortiz A., Bernardo E. et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004; 25: 1903-1910.
Cuisset T., Frere C., Quilici O. High post-treatment platelet reactivity identify low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. Thromb Haemost 2006; 4: 542-549.
Akhmedyarova L.B. Koronarnoe stentirovanie u bol'nykh IBS i narushenie chuvstvitel'nosti k antiagregantnym preparatam: printsipy diagnostiki i vozmozhnosti medikamentoznoi korrektsii: Avtoref. dis. … kand. med. nauk 2011; 123.
Taubert D., Kastrati A., Harlfinger S. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thrombosis Haemost 2004; 92: 2: 311-316.
Savchenko E.A., Grinshtein I.Yu., Savchenko A.A. Izmeneniya v sisteme gemostaza i metabolizme trombotsitov u bol'nykh s raznymi funktsional'nymi klassami stenokardii. Sib med obozrenie 2009; 3: 45-50.
Lau W., Waskell L., Watkins P. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 1: 32-37.
Saw J., Steinhubl S., Berger P. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108: 8: 921-924.
Serebruany V., Malinin A., Callahan K. Statins do not affect platelet inhibition with clopidogrel during coronary stenting. Atherosclerosis 2001; 159: 1: 239-241.
Montalescot G., Sideris G., Meuleman C. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. JACC 2006; 48: 5: 931-938.
Yong G., Rankin J., Ferguson L. Randomized trial comparing 600-with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial. Am Heart J 2009; 157: 1: 60. el-60.e 9.
Yee D., Sun C., Bergeron A. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 2005; 106: 8: 2723-2729.
Rocca B., Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 2005; 3: 8: 1597-1602.
Gurbel P., Bliden K., Hiatt B. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 23: 2908-2913.
Gurbel P., Bliden K. Durability of platelet inhibition by clopidogrel. Am J Cardiol 2003; 91: 9: 1123-1125.
Sibbing D., Stegherr J., Latz W. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009; 30: 916-922.
Mega J.L., Close S.L., Wiviott S.D. Cytochrome P450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
Mega J., Hochholzer W., Frelinger A.L. 3rd et al. Increasing Clopidogrel Based on CYP2C19 Genotype in Patients with Cardiovascular Disease AHA Sci sessions. Nov 16, 2011. http://my.americanheart.org/.
Steg Ph.G., James S.K. Acute Myocardial Infarction in patients presenting with ST-segment elevation (Management of). European Society of Cardiology. Eur Heart J 2012; 33: 2569-2619.